Clare Brennan

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

François Raffi, Anita Rachlis, Hans‐Jürgen Stellbrink et al. · The Lancet · 2013 · 537 citations

Week Results, Treatment And Prevention, Human Retrovirus +8

Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study

Bonaventura Clotet, Judith Feinberg, Jan van Lunzen et al. · The Lancet · 2014 · 492 citations

Dolutegravir Versus Darunavir, Open-label Phase 3B, Treatment And Prevention +9

Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial

François Raffi, Hans Jaeger, Eugenia Quirós-Roldán et al. · The Lancet Infectious Diseases · 2013 · 370 citations

Treatment And Prevention, Human Retrovirus, Clinical Trials +8

Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study

Jean‐Michel Molina, Bonaventura Clotet, Jan van Lunzen et al. · The Lancet HIV · 2015 · 220 citations

Dolutegravir Versus Darunavir, Treatment And Prevention, Antiviral Drug Development +11

HIV‐Associated Thrombotic Microangiopathy in the Era of Highly Active Antiretroviral Therapy: An Observational Study

Stephen Becker, Gregory Fusco, Jennifer S Fusco et al. · Clinical Infectious Diseases · 2004 · 108 citations

Immunology, Human Immunodeficiency Virus, Immunotherapy +17